We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Xellia, FDA Modify Consent Decree; Site Can Resume Production by 2017
Xellia, FDA Modify Consent Decree; Site Can Resume Production by 2017
Xellia Pharmaceuticals and the FDA have agreed on a modified consent decree so Xellia can resume manufacturing at the Bedford, Ohio, site it purchased from Ben Venue Laboratories.